Grassley Expresses Concern Over Whether National Cancer Institute Unfairly Disciplined Ethics Office for Employee Travel Scrutiny
WASHINGTON – Sen. Chuck Grassley is expressing concern over whether the National Cancer Institute unfairly disciplined its ethics director for trying to make sure agency travel complies with federal law and procedures, including those set by the institute’s parent agency, the National Institutes of Health. The travel at issue is sponsored by non-government sources, such as corporations and other private entities.
“Some government agencies have more travel than others. They should be used to transparency and scrutiny to make sure they follow the rules,” Grassley said. “National Cancer Institute executives appear to have taken issue with the scrutiny to sponsored travel given by their then-chief ethics officer. It’s important to get to the bottom of whether the ethics officer was retaliated against just for doing her job.”
Grassley wrote to the director of the National Institutes of Health and the director of the National Cancer Institute, seeking details of National Cancer Institute employees’ sponsored travel. He asked the National Cancer Institute to conduct an internal review of whether it has furnished all required information to the Office of Government Ethics and copied the Office of Government Ethics. Grassley also reminded the National Cancer Institute that interfering with federal employees’ rights to furnish information to Congress is a violation of federal law.
Next Article Previous Article
Recent News
- Wyden and Merkley Call on Oz to Resolve Chaos as States Implement Trumpcare
- Democratic Senators Demand Transparency, Accountability for Massive Rise in National Security Tariffs
- Wyden, Schumer, Warren Sound Alarm Over Trump Weaponization of the IRS Against the Free Speech Rights of Trump Opponents
- Finance Democrats Call for Halt to Unlawful Nomination of March Bell to be Health Care Inspector General
- Wyden, Welch, Cortez Masto Introduce Bill to Block Republicans’ Big Pharma Bailout, Protect Access to Life-Saving Prescription Drugs